Your Source for Venture Capital and Private Equity Financings

Venture Capital News: NAPIGEN Completes $7.85M Seed Financing

2022-07-12
WILMINGTON, DE, NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.
The Grantham Foundation and RA Capital Management led the round. Breakout Labs/Thiel Foundation, Thrive SVG Ventures, MARSBIO, and the United Mitochondrial Disease Foundation also participated in the financing.

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals. Its technology targets mitochondria and chloroplasts, two special cellular components that harbor their own DNA and are important to create energy for cells to grow. They are also critical for producing various biochemical molecules key to specific pathways and functions. NAPIGEN's genome technology has broad application in human and animal healthcare, agriculture, and industrial biotechnology.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors